XML 123 R78.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue Recognition - Effect on Statements of Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 27, 2019
Jun. 28, 2019
Mar. 29, 2019
Dec. 28, 2018
Sep. 28, 2018
Jun. 29, 2018
Mar. 30, 2018
Dec. 29, 2017
Sep. 27, 2019
Sep. 28, 2018
Sep. 29, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                      
Revenue $ 3,951,244 $ 4,010,761 $ 3,999,987 $ 4,265,349 $ 3,913,598 $ 3,971,606 $ 3,939,311 $ 3,965,118 $ 16,227,341 $ 15,789,633 $ 14,604,412
Costs and Expenses:                      
Cost of services provided                 14,532,662 13,997,911 12,995,403
Depreciation and amortization                 592,573 596,182 508,212
Selling and general corporate expenses                 367,256 377,129 299,170
Gain on sale of Healthcare Technologies                 (156,309) 0 0
Cost of services provided 3,503,280 3,594,978 3,639,959 3,794,445 3,386,380 3,526,293 3,563,009 3,522,230 15,336,182 14,971,222 13,802,785
Operating Income                 891,159 818,411 801,627
Interest and other financing costs, net                 334,987 346,535 280,985
Income Before Income Taxes                 556,172 471,876 520,642
Provision (Benefit) for Income Taxes                 107,706 (96,564) 146,455
Net income (loss)                 448,466 568,440 374,187
Less: Net income (loss) attributable to noncontrolling interest                 (83) 555 264
Net income attributable to Aramark stockholders $ 85,557 $ 82,955 $ 29,353 $ 250,682 $ 175,455 $ 72,577 $ 27,569 $ 292,284 448,549 $ 567,885 $ 373,923
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09                      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                      
Revenue                 (317,497)    
Costs and Expenses:                      
Cost of services provided                 (322,411)    
Depreciation and amortization                 18,581    
Selling and general corporate expenses                 0    
Gain on sale of Healthcare Technologies                 0    
Cost of services provided                 (303,830)    
Operating Income                 (13,667)    
Interest and other financing costs, net                 0    
Income Before Income Taxes                 (13,667)    
Provision (Benefit) for Income Taxes                 (3,554)    
Net income (loss)                 (10,113)    
Less: Net income (loss) attributable to noncontrolling interest                 0    
Net income attributable to Aramark stockholders                 (10,113)    
Calculated under Revenue Guidance in Effect before Topic 606                      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                      
Revenue                 15,909,844    
Costs and Expenses:                      
Cost of services provided                 14,210,251    
Depreciation and amortization                 611,154    
Selling and general corporate expenses                 367,256    
Gain on sale of Healthcare Technologies                 (156,309)    
Cost of services provided                 15,032,352    
Operating Income                 877,492    
Interest and other financing costs, net                 334,987    
Income Before Income Taxes                 542,505    
Provision (Benefit) for Income Taxes                 104,152    
Net income (loss)                 438,353    
Less: Net income (loss) attributable to noncontrolling interest                 (83)    
Net income attributable to Aramark stockholders                 $ 438,436